Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 1 4Phase 3 3Phase 2 3

Status

Terminated 2Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 8INDUSTRY 6NIH 4

Study Type

Interventional 6

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Thoracic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Small Cell Lung Carcinoma 1Recurrence 1Lymphoma, Follicular 1Carcinoma, Small Cell 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × etoposide phosphate × Clear all
NCT04663347 2026-06-02

EPCOREâ„¢ NHL-2

Genmab

Phase 1/2 Active not recruiting
543 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02400281 2024-07-03

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Arog Pharmaceuticals, Inc.

Phase 1/2 Completed
28 enrolled 15 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02626338 2023-12-20

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

Arog Pharmaceuticals, Inc.

Phase 1/2 Completed
16 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00537511 2019-11-19

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Celgene

Phase 1/2 Terminated
22 enrolled 13 charts

Carcinoma, Small Cell

NCT01237678 2018-01-18

A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

ImmunoGen, Inc.

Phase 1/2 Terminated
181 enrolled 17 charts
Thoracic

Small Cell Lung Carcinoma

NCT00776802 2013-06-25

GCS-100LE

La Jolla Pharmaceutical Company

Phase 1/2 Withdrawn
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡